Dana Boyle Sells 11,047 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 11,047 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $413,489.21. Following the transaction, the chief accounting officer owned 156,700 shares in the company, valued at approximately $5,865,281. This trade represents a 6.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Dana Boyle also recently made the following trade(s):

• On Monday, December 1st, Dana Boyle sold 303 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total transaction of $9,753.57.
• On Monday, October 27th, Dana Boyle sold 1,073 shares of Liquidia stock. The shares were sold at an average price of $22.93, for a total transaction of $24,603.89.

Liquidia Trading Up 5.0%

NASDAQ:LQDA opened at $39.99 on Thursday. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. The firm has a fifty day simple moving average of $32.41 and a 200-day simple moving average of $25.68. Liquidia Corporation has a 12 month low of $11.26 and a 12 month high of $40.53. The company has a market capitalization of $3.48 billion, a P/E ratio of -27.77, a PEG ratio of 0.65 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. The company had revenue of $54.34 million during the quarter, compared to analyst estimates of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The business’s revenue for the quarter was up 1106.7% compared to the same quarter last year. On average, equities research analysts anticipate that Liquidia Corporation will post -1.51 earnings per share for the current year.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent patent and court wins reduce execution and IP risk for Liquidia’s inhaled treprostinil program, supporting upside potential for commercialization. Seeking Alpha – Patent Update
• Positive Sentiment: Analyst sentiment has been upgraded recently (multiple firms raising targets and issuing Buy/Strong Buy ratings), which can attract fresh capital and lend support to the rally. Benzinga – Analyst Expectations
• Positive Sentiment: Short interest fell materially in December (reported ~18% decline), lowering potential downward pressure from short sellers and reducing immediate squeeze/volatility risk. MarketBeat – Short Interest & Court Coverage
• Neutral Sentiment: Analyst/industry write-ups note the company has won many patent battles but caution the “war is not yet won,” signaling that legal/IP progress is positive but some uncertainties remain. Seeking Alpha – Balanced Take
• Negative Sentiment: Large, coordinated insider selling occurred on Jan. 12: CEO Roger Jeffs (66,610 sh, ~$2.49M), CFO Michael Kaseta (36,932 sh, ~$1.38M), General Counsel Russell Schundler (27,289 sh, ~$1.02M) and several other insiders (collectively selling millions of dollars of stock). While insiders still retain significant stakes, the volume and scale of sales may be viewed as profit‑taking and can weigh on sentiment. MarketBeat – Insider Trades

Institutional Trading of Liquidia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Whitcomb & Hess Inc. increased its holdings in Liquidia by 2.0% in the third quarter. Whitcomb & Hess Inc. now owns 28,385 shares of the company’s stock valued at $645,000 after buying an additional 558 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Liquidia by 1.4% during the 3rd quarter. Alliancebernstein L.P. now owns 67,050 shares of the company’s stock valued at $1,525,000 after acquiring an additional 900 shares during the period. Ballentine Partners LLC increased its stake in shares of Liquidia by 10.2% in the 2nd quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock valued at $151,000 after purchasing an additional 1,119 shares in the last quarter. Steward Partners Investment Advisory LLC raised its holdings in Liquidia by 24.0% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after purchasing an additional 1,200 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ purchased a new position in Liquidia during the third quarter worth approximately $30,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

LQDA has been the topic of several research reports. Wells Fargo & Company assumed coverage on shares of Liquidia in a report on Monday, October 20th. They issued an “overweight” rating and a $31.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research note on Wednesday, October 8th. Needham & Company LLC raised their target price on shares of Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $47.00 price target on shares of Liquidia in a report on Tuesday, November 4th. Finally, Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Liquidia has an average rating of “Moderate Buy” and an average target price of $39.67.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).